Alan Wynne, MD
Endocrinology, Diabetes & Metabolism · Topeka, KSNPI 1952481145
Payments from drug & device makers
Across 2,864 payments — averaging $2404.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4.6M
- Novo Nordisk AS$1.5M
- AbbVie$261K
- Pfizer$167K
- Sanofi US Services Inc.$121K
- AstraZeneca$85K
- plus $142K from 16 others
Across 19 payments — averaging $2357.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$45K
What the payments were for
- Consulting fees$2,92538%
- Travel & lodging$3,72748%
- Food & beverage$98913%
- Education$731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 126 | $4,587,708 |
| Novo Nordisk AS | 2,553 | $1,522,501 |
| AbbVie | 21 | $260,945 |
| Pfizer | 22 | $166,562 |
| Sanofi US Services Inc. | 26 | $121,171 |
| AstraZeneca | 24 | $85,152 |
| Bayer | 33 | $80,250 |
| Boehringer Ingelheim | 6 | $16,721 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $16,692 |
| Astrazeneca UK Limited | 9 | $11,396 |
| Dompe Farmaceutici S.p.a. | 2 | $7,800 |
| GSK | 1 | $7,637 |
| Boehringer Ingelheim International GmbH | 12 | $1,124 |
| Merck | 3 | $200 |
| Novo Nordisk | 6 | $131 |
| Abbott | 1 | $98 |
| Sanofi-aventis U.S. LLC | 5 | $65 |
| Lilly USA, LLC | 5 | $54 |
| Dexcom, Inc. | 2 | $41 |
| Insulet Corporation | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Medtronic | 1 | $11 |
How this compares
$6,886,292 in reported general payments places this provider in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 12 | $26,116 |
| Novolog FlexpenInsulin Aspart | 12 | $3,928 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 22 | $1,771 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,572 |
| Levothyroxine Sodium | 50 | $542 |
| Atorvastatin Calcium | 13 | $206 |
| Glimepiride | 24 | $176 |
| Metformin Hcl ErMetformin Hcl | 25 | $173 |
| Pioglitazone Hcl | 11 | $143 |
| Methimazole | 12 | $113 |
| Metformin Hcl | 17 | $68 |
| Glipizide | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $131 | $26,11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Topeka
- Susan BrianTopeka$2.8M
- Christine UyTopeka$7K
- Bahaa Abu BakrTopeka$3K
- Jeffrey FajardoTopeka$2K
- Su Ah BaeTopeka$2K
- Francisco CorreaTopeka$2K
- Noor AddasiTopeka$741
- Dana AwadTopeka$340
- Vidita DivanTopeka$276
- Kaitlin DitchTopeka$249
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.